This is a working overview of freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-26 and is reviewed periodically as new material appears.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
=== Diabetes === There is limited evidence for the effectiveness of low-carbohydrate diets for people with type 1 diabetes. For certain individuals, it may be feasible to follow a low-carbohydrate regime combined with carefully managed insulin dosing. This can be hard to maintain and there are concerns about potential adverse health effects caused by the diet. In general, people with type 1 diabetes are advised to follow an individualized eating plan. The proportion of carbohydrate in a diet is not linked to the risk of type 2 diabetes, although there is some evidence that diets containing certain high-carbohydrate items – such as sugar-sweetened drinks or white rice – are associated with an increased risk. Some evidence indicates that consuming fewer carbohydrate foods may reduce biomarkers of type 2 diabetes. A 2019 consensus report on nutrition therapy for adults with diabetes and prediabetes the American Diabetes Association (ADA) states "Reducing overall carbohydrate intake for individuals with diabetes has demonstrated the most evidence for improving glycemia (blood sugar) and may be applied in a variety of eating patterns that meet individual needs and preferences." However, another source states that there is no good evidence that low-carbohydrate diets are better than a conventional healthy diet in which carbohydrates typically account for more than 40% of calories consumed. Low-carbohydrate dieting has no effect on the kidney function of people who have type 2 diabetes.
During the induction phase, electrolyte levels, glucose, blood counts, and liver and kidney function should be tested twice a week. In the consolidation phase, these tests should be performed weekly. Caution is advised in patients with kidney failure. During arsenic trioxide treatment, women of childbearing age and men capable of fathering children should use effective contraception. The impact of arsenic trioxide on fertility has not been thoroughly studied.
=== Release === Generally, a neurotransmitter is released via exocytosis at the presynaptic terminal in response to an electrical signal called an action potential in the presynaptic neuron. However, low-level "baseline" release also occurs without electrical stimulation. Neurotransmitters are released into and diffuse across the synaptic cleft, where they bind to specific receptors on the membrane of the postsynaptic neuron.
Sources: en.wikipedia.org
== Further reading == Reiter, Nadine; El-Shabrawi, Laila; Leinweber, Bernd; Berghold, Andrea; Aberer, Elisabeth (2011). "Calcinosis cutis". Journal of the American Academy of Dermatology. 65 (1): 15–22. doi:10.1016/j.jaad.2010.08.039. PMID 21679811. Róbert, Lili; Kiss, Norbert; Medvecz, Márta; Kuroli, Enikő; Sárdy, Miklós; Hidvégi, Bernadett (2020). "Epidemiology and treatment of calcinosis cutis: 13 years of experience". Indian Journal of Dermatology. 65 (2). Medknow: 105–111. doi:10.4103/ijd.ijd_527_18. ISSN 0019-5154. PMC 7059479. PMID 32180595.
=== 2008 days-in-a-week debate === The forums are notable for a thread titled "Full Body Workout Every Other Day?", created on May 17, 2008, in which two users had a long and intense debate over the number of days in a week. It started when user m1ndless posted: "If I go [to the gym] every other day I will be at the gym 4-5 times a week, is that over training? [...]" User steviekm3 responded: "That makes no sense. There are only 7 days in a week. If you go every other day that is 3.5 times a week." m1ndless, posting as "TheJosh" from this point on, responded: "Monday, Wednesday, Friday, Sunday. That is 4 days. How do you go 3.5 times? Do a half workout or something? lol". User Justin27 agreed with stevekm3: "7x in 2 weeks = 3.5 times a week, genius."
The word parlamento—of the same origin as Parliament in English—is used as a common name for all legislative assemblies, and hence parlamentario for the member of any of them, which can usually refer to members of:
The fat humps of camels are a source of meat in some cultures. Khlii, a camel meat dish from Algeria, is prepared in a mixture of fat from the camel's hump and kidneys. Camel hump fat is high in saturated fatty acids, with as much as 64.4% of the hump's weight basis consisting of them, and another 33.1% of its weight basis is monounsaturated fats. Bison humps, despite consisting of muscle instead of fat, are also considered a delicacy by some; William Temple Hornaday called sliced and fried bison hump "a dish fit for the gods".In markets where zebu are valued, humps can provide the breeder with higher income. In such markets, cattle may be selectively bred to have a large hump, so as to indicate a pure zebu bloodline. Siddi breeders backcross herds that have mixed too much with humpless cattle, selcting for taller bulls with larger humps, as these will be worth more than humpless bulls. Certain landforms may be named due to their resemblance of animal humps. Camel's Hump in Vermont and Buffalo Hump in Idaho are two such examples. Humans may also take their names from animal humps, such as the Comanche war chief Buffalo Hump. Some HIV-1 patients develop a fat deposit nicknamed a "buffalo hump", though this forms on the patient's neck, as opposed to between the shoulders in an actual bison.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.